|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stock W and Pui CH: Chapter 17. Acute
lymphoblastic leukemia and lymphoblastic lymphoma. ASH-SAP. pp.
489–510. 2010
|
|
3
|
Hossain MJ, Xie L and Caywood EH:
Prognostic factors of childhood and adolescent acute myeloid
leukemia (AML) survival: Evidence from four decades of US
population data. Cancer Epidemiol. 39:720–726. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rakoff-Nahoum S and Medzhitov R: Toll-like
receptors and cancer. Nat Rev Cancer. 9:57–63. 2009. View Article : Google Scholar
|
|
5
|
Chiron D, Bekeredjian-Ding I,
Pellat-Deceunynck C, Bataille R and Jego G: Toll-like receptors:
Lessons to learn from normal and malignant human B cells. Blood.
112:2205–2213. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harsini S, Beigy M, Akhavan-Sabbagh M and
Rezaei N: Toll-like receptors in lymphoid malignancies:
Double-edged sword. Crit Rev Oncol Hematol. 89:262–283. 2014.
View Article : Google Scholar
|
|
7
|
Fabricius D, Breckerbohm L, Vollmer A,
Queudeville M, Eckhoff SM, Fulda S, Strauss G, Debatin KM,
Jahrsdörfer B and Meyer LH: Acute lymphoblastic leukemia cells
treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand
facilitate enhanced anti-leukemic CTL responses. Leukemia.
25:1111–1121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Månsson A, Adner M, Höckerfelt U and
Cardell LO: A distinct Toll-like receptor repertoire in human
tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006
stimulation. Immunology. 118:539–548. 2006.PubMed/NCBI
|
|
9
|
Marshak-Rothstein A: Toll-like receptors
in systemic auto-immune disease. Nat Rev Immunol. 6:823–835. 2006.
View Article : Google Scholar
|
|
10
|
Krieg AM and Vollmer J: Toll-like
receptors 7, 8, and 9: Linking innate immunity to autoimmunity.
Immunol Rev. 220:251–269. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klonowska-Szymczyk A, Wolska A, Robak T,
Cebula-Obrzut B, Smolewski P and Robak E: Expression of toll-like
receptors 3, 7, and 9 in peripheral blood mononuclear cells from
patients with systemic lupus erythematosus. Mediators Inflamm.
2014:3814182014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Green TL, Santos MF, Ejaeidi AA, Craft BS,
Lewis RE and Cruse JM: Toll-like receptor (TLR) expression of
immune system cells from metastatic breast cancer patients with
circulating tumor cells. Exp Mol Pathol. 97:44–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu Y, Zhao Y, Huang H, Chen G, Wu X, Wang
Y, Chang W, Zhu Z, Feng Y and Wu D: Expression and function of
toll-like receptors in multiple myeloma patients: Toll-like
receptor ligands promote multiple myeloma cell growth and survival
via activation of nuclear factor-kappaB. Br J Haematol.
150:543–553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bernasconi NL, Onai N and Lanzavecchia A:
A role for Toll-like receptors in acquired immunity: Up-regulation
of TLR9 by BCR triggering in naive B cells and constitutive
expression in memory B cells. Blood. 101:4500–4504. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Genestier L, Taillardet M, Mondiere P,
Gheit H, Bella C and Defrance T: TLR agonists selectively promote
terminal plasma cell differentiation of B cell subsets specialized
in thymus-independent responses. J Immunol. 178:7779–7786. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gururajan M, Jacob J and Pulendran B:
Toll-like receptor expression and responsiveness of distinct murine
splenic and mucosal B-cell subsets. PLoS One. 2:e8632007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bourke E, Bosisio D, Golay J, Polentarutti
N and Mantovani A: The toll-like receptor repertoire of human B
lymphocytes: Inducible and selective expression of TLR9 and TLR10
in normal and transformed cells. Blood. 102:956–963. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Spaner DE, Miller RL, Mena J, Grossman L,
Sorrenti V and Shi Y: Regression of lymphomatous skin deposits in a
chronic lymphocytic leukemia patient treated with the Toll-like
receptor-7/8 agonist, imiquimod. Leuk Lymphoma. 46:935–939. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hornung V, Rothenfusser S, Britsch S, Krug
A, Jahrsdörfer B, Giese T, Endres S and Hartmann G: Quantitative
expression of toll-like receptor 1–10 mRNA in cellular subsets of
human peripheral blood mononuclear cells and sensitivity to CpG
oligodeoxynucleotides. J Immunol. 168:4531–4537. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W,
Fu T, Wang DY, Li Y, Wang HY and Wang RF: Toll-like receptor
8-mediated reversal of CD4+ regulatory T cell function.
Science. 309:1380–1384. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Crellin NK, Garcia RV, Hadisfar O, Allan
SE, Steiner TS and Levings MK: Human CD4+ T cells
express TLR5 and its ligand flagellin enhances the suppressive
capacity and expression of FOXP3 in CD4+CD25+
T regulatory cells. J Immunol. 175:8051–8059. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Caramalho I, Lopes-Carvalho T, Ostler D,
Zelenay S, Haury M and Demengeot J: Regulatory T cells selectively
express toll-like receptors and are activated by
lipopolysaccharide. J Exp Med. 197:403–411. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Corthals SL, Wynne K, She K, Shimizu H,
Curman D, Garbutt K and Reid GS: Differential immune effects
mediated by Toll-like receptors stimulation in precursor B-cell
acute lymphoblastic leukaemia. Br J Haematol. 132:452–458.
2006.PubMed/NCBI
|
|
24
|
Spaner DE, Shi Y, White D, Mena J, Hammond
C, Tomic J, He L, Tomai MA, Miller RL, Booth J, et al:
Immunomodulatory effects of Toll-like receptor-7 activation on
chronic lymphocytic leukemia cells. Leukemia. 20:286–295. 2006.
View Article : Google Scholar
|
|
25
|
Muzio M, Scielzo C, Bertilaccio MT,
Frenquelli M, Ghia P and Caligaris-Cappio F: Expression and
function of toll like receptors in chronic lymphocytic leukaemia
cells. Br J Haematol. 144:507–516. 2009. View Article : Google Scholar
|
|
26
|
Schmitt A, Li L, Giannopoulos K, Greiner
J, Reinhardt P, Wiesneth M and Schmitt M: Quantitative expression
of Toll-like receptor-2, -4, and -9 in dendritic cells generated
from blasts of patients with acute myeloid leukemia. Transfusion.
48:861–870. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rybka J, Butrym A, Wróbel T, Jaźwiec B,
Stefanko E, Dobrzyńska O, Poręba R and Kuliczkowski K: The
expression of Toll-like receptors in patients with acute myeloid
leukemia treated with induction chemotherapy. Leuk Res. 39:318–322.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rozková D, Novotná L, Pytlík R, Hochová I,
Kozák T, Bartůnková J and Spísek R: Toll-like receptors on B-CLL
cells: Expression and functional consequences of their stimulation.
Int J Cancer. 126:1132–1143. 2010. View Article : Google Scholar
|
|
29
|
Barcellini W, Imperiali FG, Zaninoni A,
Reda G, Consonni D, Fattizzo B, Lonati S, Nobili L, Zanella A and
Cortelezzi A: Toll-like receptor 4 and 9 expression in B-chronic
lymphocytic leukemia: Relationship with infections, autoimmunity
and disease progression. Leuk Lymphoma. 55:1768–1773. 2014.
View Article : Google Scholar
|
|
30
|
Webb RN, Cruse JM and Lewis RE: Decreased
TLR4 gene expression in leukemic leukocyte populations. Exp Mol
Pathol. 87:117–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bekeredjian-Ding IB, Wagner M, Hornung V,
Giese T, Schnurr M, Endres S and Hartmann G: Plasmacytoid dendritic
cells control TLR7 sensitivity of naive B cells via type I IFN. J
Immunol. 174:4043–4050. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Reid GS, She K, Terrett L, Food MR,
Trudeau JD and Schultz KR: CpG stimulation of precursor B-lineage
acute lymphoblastic leukemia induces a distinct change in
costimulatory molecule expression and shifts allogeneic T cells
toward a Th1 response. Blood. 105:3641–3647. 2005. View Article : Google Scholar : PubMed/NCBI
|
